The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
Zacks Investment Research on MSN10d
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in CardiomyopathyAlnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...
BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...
The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to CareSOUTH SAN FRANCISCO, Calif., ...
ZyVersa Therapeutics, Inc. announced promising results from a study on its Inflammasome ASC Inhibitor IC 100, which may serve as an effective treatment for obesity-associated cardiomyopathy (OAC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback